Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omegaven for Bone Health in Infants with Esophageal Atresia
NCT03127345Phase 2Withdrawn
- Sponsor
- Boston Children's Hospital
- Start
- Sep 2019
- Primary completion
- Sep 2023
- Modality
- Lipid-based Nanoparticles
01
Overview
A Phase 2 trial of eicosapentaenoic acid + docosahexaenoic acid in osteoporosis, bone fracture, sponsored by Boston Children's Hospital. Planned start Sep 2019; status: withdrawn.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
osteoporosisbone fracture
Beyond the preview
Go deeper on NCT03127345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03127345.